IGC Pharma Inc (AMEX:IGC) has a beta value of 1.32 and has seen 0.47 million shares traded in the last trading session. The company, currently valued at $27.80M, closed the last trade at $0.36 per share which meant it gained $0.02 on the day or 4.06% during that session. The IGC stock price is -152.78% off its 52-week high price of $0.91 and 27.78% above the 52-week low of $0.26. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.39 million shares traded. The 3-month trading volume is 349.11K shares.
The consensus among analysts is that IGC Pharma Inc (IGC) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.03.
IGC Pharma Inc (AMEX:IGC) trade information
Sporting 4.06% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the IGC stock price touched $0.36 or saw a rise of 2.07%. Year-to-date, IGC Pharma Inc shares have moved 6.85%, while the 5-day performance has seen it change 6.85%. Over the past 30 days, the shares of IGC Pharma Inc (AMEX:IGC) have changed -2.74%. Short interest in the company has seen 1.22 million shares shorted with days to cover at 2.29.
IGC Pharma Inc (IGC) estimates and forecasts
Figures show that IGC Pharma Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -14.73% over the past 6 months, with this year growth rate of 50.00%, compared to 16.70% for the industry. Revenue growth from the last financial year stood is estimated to be -12.04%.
1 analysts offering their estimates for the company have set an average revenue estimate of 204k for the current quarter. 1 have an estimated revenue figure of 295k for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -13.79% over the past 5 years.
IGC Dividends
IGC Pharma Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
IGC Pharma Inc (AMEX:IGC)’s Major holders
Insiders own 7.92% of the company shares, while shares held by institutions stand at 22.00% with a share float percentage of 23.89%. Investors are also buoyed by the number of investors in a company, with IGC Pharma Inc having a total of 28.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 0.7 million shares worth more than $0.31 million. As of 2024-06-30, BLACKROCK INC. held 1.1961% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 0.65 million shares as of 2024-06-30. The firm’s total holdings are worth over $0.28 million and represent 1.0965% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 1.59% shares in the company for having 630.22 shares of worth $0.22 million while later fund manager owns 387.25 shares of worth $0.13 million as of Oct 31, 2024 , which makes it owner of about 0.98% of company’s outstanding stock.
